Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 147

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 147
---
 diseases |  17/050,430 | 4/26/2018 | 10/23/2020 | 11,446,351 | 8/31/2022 | 4/25/2039  | Issued  | LifeArc   |
| China         | Composition for treating one or more estrogen related diseases |   112041028 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | Life Agco |
| Israel        | Composition for treating one or more estrogen related diseases |      277876 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | LifeArc   |
| Japan         | Composition for treating one or more estrogen related diseases |  2021522227 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | LifeArc   |
| Mexico        | Composition for treating one or more estrogen related diseases |  2020011341 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | LifeArc   |

<div align='center'>99

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83</div>

| Country       
 Name          | Title                                     | Application 
         No. | Priority 
 Date     | Filed      
 Date       |     Patent 
        No. | Issue     
 Date      | Projected  
 Expiration 
 Date       | Status  | Assignee      
 (s)           |
| United States | Reconstitutable teverelix-TFA composition |  17/254,859 | 7/5/2018 | 12/22/2020 | 11,633,453 | 4/5/2023  | 7/2/2039   | Issued  | Antev Limited |
| United States | Reconstitutable teverelix-TFA composition |  18/122,991 | 7/5/2018 | 3/17/2023  |            |           | 7/2/2039   | Pending | Antev Limited